What changed today in Metabolic: 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
The signal
NPHLA tracked 3 new official records on this desk today: 3 new studies.
Why this matters
GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.
What changed
- New research in Expert review of clinical pharmacology: “Rethinking endpoints for anti-obesity pharmacotherapy in patients with hr+ early breast cancer receiving endocrine therapy: from body weight and BMI to body composition”.[1]
- New research in Clinical nutrition ESPEN: “Semaglutide Versus Diet-Based Weight Loss in Obesity and Heart Failure with Reduced Ejection Fraction (FIT-HF): Protocol for a Randomized Controlled Trial”.[2]
- New research in Pulmonary therapy: “Incretin-Based Therapies and Pulmonary Fibrosis: Preclinical Evidence, Body Composition, and Translational Perspectives: A Narrative Review”.[3]
Who this affects
- Weight-management clinics
- Med spas
- Pharmacists
- Prescribers
- Medical directors
- Practice owners & operators
What to watch next
No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.
NPHLA takeaway
These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.
Source file
- [1]
- [2]
- [3]
Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.